First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)1127-1132
Number of pages6
JournalProstate
Volume83
Issue number12
DOIs
StatePublished - Sep 2023
Externally publishedYes

Keywords

  • adverse events
  • androgen deprivation therapy
  • castration-resistant prostate cancer
  • quality of life

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this